Nab-paclitaxel-oxaliplatin-S-1 vs FOLFOX in locally advanced gastric cancer: Efficacy and postoperative disease-free survival prediction

doi:10.4251/wjgo.123857

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 11

This Article

(2)

(0)

(85)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article (XML)

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123857
Published online Nov 15, 2026. doi: 10.4251/wjgo.123857

Nab-paclitaxel-oxaliplatin-S-1 vs FOLFOX in locally advanced gastric cancer: Efficacy and postoperative disease-free survival prediction

Bao-Yan Ji, Lu-Lu Qi, De-Yan Fan, Yun Zhang, Li He, Kuan Zhang, Zhi-Bo Liu

Bao-Yan Ji, De-Yan Fan, Yun Zhang, Li He, Kuan Zhang, Zhi-Bo Liu, Department of Oncology, Qinghai Red Cross Hospital, Xining 810000, Qinghai Province, China

Lu-Lu Qi, Department of Otolaryngology, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China

Co-first authors: Bao-Yan Ji and Lu-Lu Qi.

Co-corresponding authors: Kuan Zhang and Zhi-Bo Liu.

Author contributions: Ji BY and Qi LL contributed equally to this work, as they are co-first authors; Liu ZB and Zhang K supervised the project, they are co-corresponding authors; Ji BY and Qi LL performed the main experiments, analyzed the data, and drafted the manuscript; Fan DY, Zhang Y, and He L contributed to data collection, analysis, and manuscript revision; all authors reviewed and approved the final manuscript.

AI contribution statement: Since we are not native English speakers, after completing the writing in our native language, we used translation software to translate it. Additionally, we have sent the revised manuscript to a professional editing company for language refinement.

Supported by the Qinghai Red Cross Hospital Institutional Self-selected Research Project, No. YNZXKT2026023.

Institutional review board statement: This study approved by the Ethics Committee of the Affiliated Hospital of Qinghai University, No. P-SL-2022-035.

Informed consent statement: Written informed consent was obtained from all participants.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Data sharing statement: The datasets used and/or analyzed during the current study are not publicly available due to privacy or ethical restrictions.

Corresponding author: Zhi-Bo Liu, MD, Professor, Department of Oncology, Qinghai Red Cross Hospital, No. 55 South Street, Chengzhong District, Xining 810000, Qinghai Province, China. liuzhibo0965@163.com

Received: June 3, 2026
Revised: June 17, 2026
Accepted: July 17, 2026
Published online: November 15, 2026
Processing time: 150 Days and 12.2 Hours

Core Tip

Core Tip: This retrospective two-center study compared FOLFOX and P-SOX regimens in patients with locally advanced gastric cancer undergoing perioperative chemotherapy and D2 radical gastrectomy. P-SOX showed numerically higher radiological and pathological response rates than FOLFOX, but the differences were not statistically significant. Survival curves also suggested a favorable trend for P-SOX without significant disease-free survival or overall survival improvement. A least absolute shrinkage and selection operator-Cox-based nomogram incorporating clinical tumor node metastasis stage, tumor regression grade response, and pre-chemotherapy tumor diameter was developed to predict 18-month, 24-month, and 36-month disease-free survival, providing a practical tool for postoperative recurrence risk stratification.